ppRB.sup.110 -phosphoprotein the retinoblastoma susceptibility gene product
US4942123A · kind A · utility
13Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 17, 1987 |
| Grant date | Jul 17, 1990 |
| Priority date | — |
| Expiry date | Sep 17, 2007 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/828
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
This invention relates in general to a phosphoprotein product of the retinoblastoma susceptibility gene. In particular, this invention relates to a phosphoprotein ppRB.sup.110 primarily located in the cell nucleus which has a DNA binding activity. The invention also relates to the amino acid sequence of the phosphoprotein and to the specific purified anti-retinoblastoma phosphoprotein antibody. The invention further relates to a method of diagnosing retinoblastoma and other retinoblastoma gene involved cancers, treating such kind of cancers and regulating the oncogenicity of other genes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.